Jinling Pharmaceutical (SHE:000919) agreed to postpone the ready-to-use date of the core active pharmaceutical ingredient and high-end pharmaceutical intermediates common production platform to 2028, according to a Wednesday filing on the Shenzhen bourse.
The platform was supposed to be scheduled to start in March this year but has to be moved to control the overall project quality and meet management requirements.
The pharmaceutical company's shares rose over 1% at the close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.